NETCast

In this episode of NETCast, we explore two increasingly important, and often underrecognized, aspects of neuroendocrine tumor care: hereditary risk assessment and long-term systemic complications, including carcinoid heart disease.Hosted by Dr. Daniel Halperin and featuring experts in genetic counseling and cardio-oncology, the discussion examines how multidisciplinary NET care teams are evolving beyond traditional oncology models to better support patients across the full continuum of disease.Together, the panel discusses hereditary syndromes, integrating genetic counseling into NET care, recognizing cardiac complications earlier, survivorship considerations, and the importance of communication across multidisciplinary care teams. The conversation also highlights how comprehensive NET programs are increasingly expanding to address the broader systemic and long-term needs of patients living with neuroendocrine tumors.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, we explore the patient and caregiver experience beyond the clinic walls and examine what truly patient-centered care looks like within the neuroendocrine tumor community. Hosted by Dr. Daniel Halperin and featuring leaders from the Neuroendocrine Tumor Research Foundation and Neuroendocrine Cancer Foundation, this conversation focuses on the emotional realities of living with NETs, caregiver advocacy, the importance of community and peer support, and how healthcare teams can better support patients and families throughout the disease journey. Together, the panel shares practical insights and personal perspectives on building trust, reducing isolation, and improving quality of life in rare disease care.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Recorded live at the NANETS Columbus Regional Conference, this episode of NETCast explores the multidisciplinary strategies that drive long-term tumor control in patients with advanced neuroendocrine tumors (NETs).Hosted by Drs. Jordan Cloyd and Bhavana Konda, the discussion brings together experts in medical oncology, surgical oncology, and gastroenterology to examine how treatment decisions evolve over the course of a patient's disease. Rather than focusing on a single intervention, the conversation highlights the importance of balancing systemic therapy, surgery, endoscopic management, quality of life, and patient goals through coordinated multidisciplinary care.Through practical discussion and real-world perspectives, the panel explores treatment sequencing, the evolving role of cytoreductive surgery, when less invasive management may be appropriate, and how multidisciplinary tumor boards help navigate complex clinical decisions. Together, the panel shares insights into how collaboration across specialties leads to more thoughtful, individualized care and better long-term outcomes for patients living with advanced neuroendocrine tumors.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, host Dr. Emil Lou is joined by a multidisciplinary panel of experts and a patient advocacy perspective to explore one of the most nuanced aspects of neuroendocrine tumor care: how physicians communicate uncertainty when the data are limited, evolving, or open to interpretation.Featuring perspectives from medical oncology, surgical oncology, nuclear medicine, and patient advocacy, the discussion examines the real-world challenges of navigating gray areas in NET care where multiple treatment paths may be reasonable and patient preferences play a critical role. The panel discusses how clinicians approach conversations when evidence is incomplete, communicate risk and treatment options, manage differing opinions within multidisciplinary teams, and build trust with patients facing complex decisions.Together, the group offers candid reflections and practical insights on balancing science, communication, and compassion in modern NET care.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this live recording from the Nashville Regional, we will explore the real-world impact of multidisciplinary NET specialty centers, particularly for patients initially diagnosed or managed in community settings. What structurally changes when a patient transitions from community-based care to an academic institution? And further, what distinguishes a general academic center from a dedicated NET specialty center?This conversation will examine how multidisciplinary tumor board functions as the operational engine behind complex decision-making, the role of pathology reassessment, referral timing, access to specialized imaging and therapies, and how community and specialty centers can collaborate to optimize outcomes for patients with neuroendocrine tumors.The focus will be on systems of care and collaboration, rather than on a specific therapy or guideline update.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.